glp 1 agonist pcos Rising use of GLP-1 medications among women with GLP1-Based Multi-Agonist Therapy for PCOS
Description
Verma S, Poulter NR, Bhatt DL, et al

Cardiovasc Diabetol (2022) 21:169

156 Administering 1.5 mg of dulaglutide reportedly decreased gastric emptying by roughly threefold, with the initial MRT (0.27 h) increasing to 0.84 h

Here, we review the scarce literature on the use of different GLP-1RAs in BAD treatment and discuss the potential of different GLP-1RAs in the context of their pharmacokinetic profiles, which we speculate may be important determinants of their mode of actions and, thus, pharmacodynamics in BAD

Today 22 , 17071718 (2017)
Avogaro A, Fadini GP
